Rheinmetall's Twin Narratives: A €500m Bundeswehr Order Sits Uneasily Against a €2.7bn Delivery Slip

Rheinmetall's record €80.5bn backlog masks delivery delays in key Bundeswehr programs, triggering mixed analyst ratings and a 42% stock drop from highs.

The Düsseldorf-based defence group Rheinmetall is living a double life right now. On any given week, the company can announce a fresh Bundeswehr contract worth half a billion euros and, within days, face fresh scrutiny over delayed weapons programmes that threaten its delivery schedule. This week offered both.

The Bundeswehr has called off an additional 149 mobile field hospital stations from an existing framework agreement, a contract valued at more than €500m gross. Production is slated to begin in the first quarter of 2027. It is the latest addition to an order book that has already blown past the €80bn mark — the company reported a record €80.5bn backlog alongside its second-quarter results roughly three weeks ago.

Yet the share price has barely registered the news. On Monday, Rheinmetall stock traded at €1,157.60, effectively flat against Friday's close. The muted response follows a softer session earlier in the week when the shares dipped 1.3 percent to €1,141.60, extending a seven-day losing streak of 6.1 percent. Over a 30-day horizon, the equity has gained 12 percent, but it remains 25 percent below its level at the start of the year and sits a full 42 percent beneath its 52-week high from 3 October 2025.

The Delivery Problem at the Heart of the Story

The friction between headline-grabbing orders and operational reality came into sharper focus on Thursday, when Capital magazine reported significant slippage in two major Bundeswehr programmes. The 123 "Heavy Weapons Carrier Infantry" vehicles being built in Australia — a project worth €2.7bn — are running at least eleven months late, hampered by quality deficiencies and insufficient technical maturity. Separately, the first Skyranger 30 air-defence systems will now arrive from mid-2027 rather than mid-2026 as originally planned.

The news prompted BÖRSE ONLINE to advise against buying the stock, pointing to the operational risks embedded in the delayed deliveries. A day later, Morningstar reaffirmed its "buy" rating on the shares — a striking divergence that underscores just how far apart market observers have drifted in their read on the company.

That split extends to the sell-side as well. Jefferies lifted its price target to €1,350 on 14 August while keeping a buy recommendation, and RBC upgraded the stock to "buy" on 11 August. JPMorgan, by contrast, held the shares at "neutral" on 17 August — albeit with the same €1,350 target, a reminder that an optimistic valuation does not always translate into a bullish call. The most bearish voice belongs to mwb research, which cut its rating from "hold" to "sell" on 8 August and trimmed its price objective from €1,150 to €1,050.

The F126 Shadow

Much of the uncertainty traces back to the collapse of the F126 frigate programme, a setback that forced Rheinmetall to lower its full-year revenue guidance by up to €300m. The company's chief executive said in early August that he was "very dissatisfied" with the outcome, while media reports pointed to growing execution risks across the group. Since that announcement, the stock has barely moved, adding just 0.7 percent.

The operational numbers, however, tell a more resilient story. Second-quarter operating profit jumped 115 percent year-on-year, and the order intake continues to flow. Beyond the field hospital contract, Rheinmetall and sensor specialist Hensoldt demonstrated last week — during the Bundeswehr's "Timber Express 2026" exercise — the successful integration of the Twinvis passive radar into the Skymaster command and weapons engagement system, a step forward in NATO-compatible sensor-data networking. The collaboration signals Rheinmetall's deepening involvement in complex air-defence solutions alongside its traditional vehicle and ammunition production, a segment where European armed forces are investing heavily as threat perceptions shift.

A Stock Caught Between Growth Story and Execution Risk

For investors, the picture is genuinely two-sided. The delivery delays at the weapons carrier and air-defence programmes involve large, high-value contracts that could weigh on near-term revenue recognition. At the same time, the record backlog, the steady stream of smaller, predictable orders like the medical stations, and partnerships — including work with Boeing on bringing Collaborative Combat Aircraft technology to Germany — provide a solid foundation for long-term growth.

The next test comes on 27 August, when Rheinmetall's management appears at the DZ Bank Expert Day. Investors will be watching closely to see how the executive team reconciles the conflicting signals: fresh contract wins in the medical and sensor divisions on one hand, programme risks and a trimmed revenue outlook on the other. Until then, the shares look likely to remain trapped between the growth narrative and the execution questions that have dogged the company since the F126 blow-up.